background
high
global
preval
latent
tb
infect
ltbi
key
challeng
endem
set
distinguish
patient
activ
tb
patient
overlap
clinic
symptom
without
activ
tb
coexist
ltbi
current
method
insuffici
accur
plasma
proteom
fingerprint
resolv
difficulti
provid
molecular
snapshot
defin
diseas
state
use
develop
pointofcar
diagnost
method
plasma
clinic
data
obtain
prospect
patient
attend
commun
tb
clinic
peru
household
contact
plasma
subject
highthroughput
proteom
profil
mass
spectrometri
statist
pattern
recognit
method
use
defin
mass
spectral
pattern
distinguish
patient
activ
tb
symptomat
control
without
ltbi
result
patient
activ
tb
symptomat
control
patient
respiratori
symptom
without
activ
tb
investig
activ
tb
patient
distinguish
undifferenti
symptomat
control
accuraci
sensit
specif
symptomat
control
ltbi
accuraci
sensit
specif
symptomat
control
without
ltbi
accuraci
sensit
specif
show
activ
tb
distinguish
accur
ltbi
symptomat
clinic
attend
use
plasma
proteom
fingerprint
translat
biomark
deriv
studi
robust
afford
pointofcar
format
signific
implic
recognit
control
activ
tb
high
preval
set
tuberculosi
lead
bacteri
caus
death
worldwid
estim
million
new
case
activ
diseas
million
death
per
year
much
burden
diseas
lie
develop
world
annual
incid
reach
per
certain
region
new
unrecognis
case
drive
epidem
transmiss
usual
occur
index
case
diagnos
multidrug
resist
case
hiv
coinfect
complic
control
effort
pulmonari
tb
frequent
clinic
transmiss
manifest
activ
diseas
rapid
diagnosi
treatment
critic
prevent
transmiss
global
burden
activ
tb
occur
background
quiescent
latent
tb
infect
ltbi
affect
one
third
world
popul
higher
proport
popul
tbendem
area
respiratori
constitut
symptom
overlap
pulmonari
tb
common
commun
tb
endem
scenario
challeng
distinguish
symptomat
patient
activ
tb
latent
diseas
whose
present
symptomatolog
attribut
infecti
inflammatori
process
term
rapid
diagnosi
sputum
microscopi
identifi
approxim
patient
activ
pulmonari
tb
convers
interferon
gamma
releas
assay
igra
repres
major
advanc
detect
latent
tb
distinguish
activ
tb
symptomat
patient
latent
infect
context
overlap
ltbi
activ
tb
nonspecif
clinic
manifest
present
formid
obstacl
rapid
recognit
activ
tb
time
appropri
target
antitb
chemotherapi
chemoprophylaxi
practic
difficulti
may
give
rise
type
therapeut
error
first
instanc
erron
diagnosi
activ
tb
symptomat
patient
ltbi
may
result
inappropri
administr
full
cours
tb
treatment
convers
offer
chemoprophylaxi
patient
suppos
ltbi
activ
tb
recogn
drive
emerg
drug
resist
pulmonari
tb
characteris
granuloma
format
caseat
ultim
cavit
reflect
complex
interplay
distinct
compon
innat
acquir
immun
respons
pathogen
tradit
serolog
analysi
singl
circul
protein
notori
unreli
tb
diagnosi
contrast
pattern
circul
protein
could
provid
access
readout
pathophysiolog
statu
discoveri
discriminatori
biomark
could
open
way
develop
new
pointofcar
test
base
later
flow
format
dipstick
proteom
analysi
use
surfac
enhanc
laser
desorpt
ionis
time
flight
selditof
mass
spectrometri
high
throughput
profil
methodolog
enabl
rapid
comparison
protein
pattern
larg
number
patient
conceptu
approach
employ
present
studi
term
proteom
fingerprint
base
principl
distinct
combin
circul
protein
character
differ
diseas
state
strategi
appli
discoveri
discriminatori
proteom
pattern
rang
diseas
includ
cancer
vascular
diseas
infecti
diseas
previous
demonstr
proteom
pattern
base
profil
distinguish
activ
tb
healthi
symptomat
control
present
studi
hypothes
plasma
proteom
differ
would
also
distinguish
patient
activ
tb
without
activ
tb
overlap
clinic
symptom
irrespect
coexist
ltbi
show
use
approach
inde
discrimin
accur
patient
group
particip
gave
written
inform
consent
research
approv
intern
accredit
ethic
committe
includ
universidad
peruana
cayetano
heredia
lima
peru
imperi
colleg
london
london
unit
kingdom
studi
involv
adult
year
age
inform
consent
obtain
next
kin
carer
guardian
behalf
young
adult
involv
studi
particip
recruit
period
two
year
adult
age
year
attend
commun
tb
clinic
serv
popul
shantytown
ventanilla
outskirt
lima
peru
figur
patient
underw
local
standard
clinic
workup
tb
includ
consecut
sputum
sampl
microscopi
cultur
particip
studi
chang
patient
routin
clinic
manag
local
incid
tb
popul
per
tb
case
hiv
neg
recruit
patient
activ
tb
individu
term
symptomat
control
present
respiratori
symptom
suspici
tb
tb
subsequ
exclud
activ
tb
case
recruit
basi
posit
sputum
microscopi
subsequ
confirm
cultur
mycobacteri
cultur
autom
liquid
cultur
bactec
mgit
tm
bd
well
microscop
observ
drug
suscept
mod
assay
previous
establish
standard
local
laboratori
protocol
sinc
adopt
standard
oper
procedur
nation
tb
programm
peru
symptomat
control
patient
respiratori
symptom
without
activ
tb
recruit
persist
cough
one
follow
clinic
featur
fever
weight
loss
decreas
appetit
haemoptysi
symptomat
control
sputum
smear
cultur
exclud
activ
tb
follow
month
confirm
cultur
becom
posit
reclassifi
accordingli
addit
tb
case
symptomat
control
identifi
trace
household
contact
sputum
smear
cultur
obtain
symptomat
ifnc
releas
assay
igra
quantiferontb
gold
intubeh
perform
particip
latent
tb
defin
posit
quantiferonh
assay
absenc
clinic
microbiolog
evid
activ
tb
tuberculin
skin
test
tst
limit
valu
diagnosi
activ
tb
carri
activ
tb
patient
group
carri
tst
symptomat
control
group
ml
blood
sampl
obtain
particip
edta
blood
collect
tube
subsequ
plasma
separ
three
addit
aliquot
obtain
time
quantiferonhtb
gold
tube
assay
plasma
obtain
initi
tb
treatment
otherwis
plasma
taken
within
day
treatment
blood
sampl
transfer
central
laboratori
ice
plasma
separ
rpm
minut
aliquot
frozen
hour
follow
collect
quantiferonh
tb
gold
tube
assay
perform
accord
manufactur
instruct
cellesti
plc
sydney
australia
plasma
profil
use
surfac
enhanc
laser
desorpt
ionisationtim
flight
selditof
mass
spectrometri
sampl
underw
singl
freezethaw
cycl
prior
analysi
sampl
code
blind
randomis
applic
onto
weak
cation
exchang
proteinchiph
array
biorad
duplic
previous
describ
proteinchiph
includ
qualiti
control
standard
deriv
singl
healthi
individu
place
random
liquid
handl
step
autom
use
biomek
laboratori
autom
workstat
beckman
coulter
well
bioprocessorh
biorad
mass
spectra
gener
autom
system
biorad
proteinchiph
reader
mass
spectra
data
collect
analys
use
proteinchiph
data
manag
client
softwar
biorad
inc
spectra
gener
high
nj
low
nj
laser
energi
mass
focu
set
da
da
respect
spectra
normalis
total
ion
current
start
minimum
masscharg
mz
spectra
normalis
factor
outsid
mean
standard
deviat
remov
remain
spectra
renormalis
total
ion
current
spectral
peak
correspond
masscharg
mz
cluster
detect
cluster
use
proteinchiph
data
manag
client
softwar
biorad
inc
autodetect
peak
cluster
two
step
first
step
signal
nois
ratio
valley
depth
use
minimum
peak
threshold
spectra
second
step
signal
nois
ratio
valley
depth
chosen
cluster
window
set
peak
width
express
differ
map
perform
mz
rang
instrument
calibr
perform
use
peptid
protein
calibr
biorad
reproduc
determin
measur
interproteinchiph
coeffici
variat
cv
qualiti
control
spectra
base
peak
spectrum
intens
overal
interchip
cv
qualiti
control
sampl
consist
similar
studi
highli
abund
proteinspeptid
suppress
signal
lower
abund
analyt
complex
mixtur
crude
plasma
selditof
spectra
gener
crude
prefraction
plasma
determin
whether
access
deeper
proteom
yield
addit
diagnost
inform
anionex
visual
covari
within
mass
spectral
profil
use
princip
compon
analysi
pca
pca
encapsul
covari
within
set
variabl
extract
rank
set
independ
factor
princip
compon
first
compon
encompass
high
proport
inform
content
multivari
dataset
plot
patient
respect
first
compon
space
colorcod
accord
patient
group
although
pca
use
visual
data
provid
classif
rule
discrimin
patient
categori
find
discriminatori
proteom
pattern
adopt
supervis
learn
approach
patient
categori
use
train
algorithm
deriv
classif
rule
use
support
vector
machin
svm
method
briefli
use
cross
valid
select
paramet
svm
final
model
paramet
select
gave
overal
highest
accuraci
across
whole
fold
cross
valid
next
select
subset
relev
mass
cluster
use
recurs
featur
elimin
rfe
algorithm
rank
variabl
base
contribut
classifi
obtain
accuraci
estim
classifi
took
random
resampl
origin
data
use
train
test
select
final
classifi
one
produc
highest
accuraci
requir
smallest
number
mz
cluster
result
express
sensit
specif
accuraci
proport
correct
classif
receiv
oper
characterist
roc
curv
assess
differ
perform
classifi
deriv
crude
prefraction
plasma
compar
mean
valu
sensit
specif
accuraci
use
unpair
test
comparison
categor
data
fisher
exact
test
patient
activ
tb
symptomat
control
recruit
figur
patient
activ
tb
smear
cultur
posit
remaind
either
smear
cultur
posit
symptomat
control
ltbi
basi
posit
quantiferongold
assay
symptomat
control
clinic
featur
overlap
activ
tb
patient
includ
cough
haemoptysi
fever
night
sweat
weight
loss
although
symptom
durat
gener
longer
among
tb
patient
similar
proport
tb
patient
symptomat
control
report
previou
histori
tb
vs
proport
report
histori
tb
higher
among
control
ltbi
among
without
reach
statist
signific
patient
activ
tb
lower
bmi
time
recruit
compar
symptomat
control
vs
expect
higher
proport
patient
ltbi
base
posit
igra
posit
tst
mm
compar
without
ltbi
vs
higher
proport
femal
patient
among
symptomat
control
among
tb
group
effect
potenti
bia
discuss
key
clinic
featur
particip
group
given
tabl
plot
crude
plasma
global
protein
express
profil
heat
map
figur
show
spectra
pattern
activ
tb
patient
unhealthi
control
strike
area
upregul
tb
patient
seen
kda
region
seri
protein
peak
seen
red
amongst
tb
patient
figur
parallel
area
upregul
seen
kda
third
smaller
area
seen
kda
region
figur
inspect
detail
spectra
kda
region
figur
reveal
complex
peak
region
abund
patient
activ
tb
assess
overal
separ
patient
group
pca
mass
spectra
crude
prefraction
plasma
figur
ab
figur
patient
sampl
plot
space
defin
first
princip
compon
spectra
patient
activ
tb
purpl
sphere
cluster
rel
tightli
togeth
well
separ
symptomat
control
patient
blue
green
sphere
regardless
ltbi
analysi
howev
clearli
separ
symptomat
control
without
ltbi
blue
green
sphere
respect
svm
classifi
distinguish
activ
tb
class
symptomat
control
roc
curv
figur
af
summar
perform
classifi
term
tradeoff
sensit
specif
differ
comparison
case
area
curv
auc
exceed
irrespect
whether
crude
prefraction
plasma
analyz
indic
high
level
discrimin
tabl
tabl
summar
perform
classifi
discrimin
activ
latent
tuberculosi
symptomat
patient
use
number
select
relev
mz
cluster
tabl
bracket
possibl
distinguish
patient
activ
tb
undifferenti
symptomat
control
partial
overlap
respiratori
constitut
symptom
overal
accuraci
use
crude
spectra
relev
mz
cluster
tabl
tabl
figur
higher
specif
activ
tb
vs
achiev
use
prefraction
plasma
total
relev
mz
cluster
tabl
tabl
figur
notabl
level
discrimin
achiev
despit
nearli
half
symptomat
control
ltbi
tabl
investig
influenc
background
ltbi
classifi
perform
separ
comparison
made
activ
tb
symptomat
control
either
without
ltbi
comparison
activ
tb
could
distinguish
symptomat
control
overal
classifi
accuraci
least
tabl
tabl
figur
cf
tabl
activ
tb
readili
distinguish
symptomat
control
without
ltbi
use
crude
fraction
plasma
overal
accuraci
sensit
specif
least
tabl
tabl
figur
e
f
tabl
main
influenc
ltbi
among
symptomat
control
reduc
classifi
specif
reflect
higher
proport
fals
posit
strikingli
plasma
prefraction
improv
specif
use
four
mz
cluster
tabl
tabl
figur
c
address
issu
gender
bia
case
control
reanalys
data
determin
whether
classifi
base
proteom
profil
could
reliabl
discrimin
male
femal
found
case
suggest
gender
major
confound
analysi
test
new
classifi
train
male
patient
alon
discrimin
activ
tb
symptomat
control
appli
train
classifi
femal
subject
classifi
nevertheless
still
capabl
classifi
tb
accuraci
approxim
also
confirm
presenc
differenti
express
serum
amyloid
saa
kda
transthyretin
kda
peak
complex
emerg
previou
studi
import
inform
marker
activ
tb
saa
identifi
specif
immunodeplet
data
shown
studi
shown
distinct
pattern
plasma
protein
distinguish
patient
activ
tb
nontb
patient
overlap
clinic
featur
even
presenc
ltbi
reinforc
substanti
extend
previou
find
first
show
proteom
pattern
could
use
diagnost
approach
activ
tb
shown
proteom
pattern
mere
reflect
presenc
tb
infect
per
se
rather
use
identifi
activ
tb
even
highli
tbendem
set
high
preval
respiratori
symptom
background
ltbi
b
activ
tb
vs
symptomat
control
use
crude
prefraction
plasma
respect
c
activ
tb
vs
symptomat
control
latent
tb
use
crude
prefraction
plasma
respect
e
f
activ
tb
vs
symptomat
control
without
latent
tb
use
crude
prefraction
plasma
respect
roc
deriv
random
traintest
resampl
data
error
bar
show
standard
deviat
area
curv
auc
shown
centr
plot
tabl
discrimin
activ
latent
tuberculosi
symptomat
patient
abil
discrimin
rapidli
symptomat
patient
activ
tb
nontubercul
diseas
profound
implic
individu
clinic
manag
tb
control
program
exampl
current
diagnost
limit
frequent
result
mani
patient
resourcepoor
set
treat
empir
commun
acquir
pneumonia
eventu
diagnosi
activ
tb
may
lead
ongo
transmiss
interv
preced
diagnosi
well
greater
individu
morbid
altern
strategi
empir
antitb
chemotherapi
sometim
employ
cost
toxic
logist
often
preclud
adjunct
convent
microbiolog
diagnosi
activ
tb
widespread
use
includ
tst
igra
use
tst
diagnosi
activ
tb
high
preval
set
greatli
limit
poor
specif
activ
tb
reactiv
also
seen
ltbi
previou
bcg
vaccin
exposur
environment
mycobacteria
recent
introduct
igra
clinic
practic
resolv
key
diagnost
issu
inabl
distinguish
activ
tb
ltbi
frequent
fals
neg
result
acut
activ
tb
limit
especi
problemat
high
preval
set
thu
diagnost
overcom
limit
urgent
requir
would
major
advanc
manag
global
tb
pandem
recent
report
tnfalpha
tbspecif
use
differenti
latent
infect
activ
tb
sensit
moreov
studi
reli
polychromat
flow
cytometri
limit
feasibl
translat
high
preval
set
contrast
approach
provid
improv
accuraci
detect
relev
protein
biomark
plasma
despit
discoveryphas
approach
use
sophist
proteom
methodolog
identif
relev
plasma
protein
lead
clear
translat
path
antibodybas
pointofcar
devic
use
measur
plasma
protein
futur
increas
interest
identif
novel
biomark
tb
context
diagnosi
treatment
respons
monitor
predict
relaps
reactiv
surrog
vaccin
protect
studi
focus
individu
marker
secret
tuberculosi
antigen
serolog
respons
microbiolog
indic
host
inflammatori
marker
mix
result
grow
recognit
advantag
use
combinatori
biomark
panel
omicsbas
method
achiev
suffici
level
accuraci
howev
rel
studi
util
strategi
proteom
fingerprint
biomark
discoveri
appli
past
decad
varieti
diseas
state
particularli
sphere
cancer
diagnost
power
approach
reflect
recent
grant
fda
approv
novel
blood
test
deriv
seldibas
fingerprint
method
distinguish
malign
benign
ovarian
tumour
mani
infecti
diseas
clinic
import
distinct
made
differ
manifest
associ
underli
pathogen
exampl
distinguish
colon
latent
diseas
activ
infect
obviou
clinic
therapeut
implic
tb
clear
case
point
proteom
fingerprint
enorm
potenti
defin
distinguish
diseas
state
recent
receiv
attent
area
circul
sampl
deep
tissu
throughout
bodi
local
proteom
chang
organ
lung
reflect
plasma
proteom
moreov
host
modul
pathogen
like
gener
chang
pattern
protein
express
associ
differ
clinic
manifest
thu
plasma
proteom
respons
plausibl
index
diseas
state
proteom
pattern
highli
dynam
may
possibl
defin
reflect
stage
progress
latenc
activ
diseas
howev
complex
plasma
proteom
enorm
dynam
rang
solut
concentr
mean
detect
inform
lower
abund
protein
particularli
challeng
possibl
differ
activ
tb
ltbi
symptomat
patient
reflect
better
lower
abund
protein
easili
detect
crude
plasma
may
explain
higher
specif
activ
tb
obtain
prefraction
compar
crude
plasma
spectra
gold
standard
use
defin
patient
group
studi
notori
imperfect
exampl
activ
tb
defin
posit
microbiolog
possibl
patient
design
symptomat
control
may
actual
smear
cultur
neg
tb
might
result
underestim
specif
diagnost
pattern
activ
tb
although
month
followup
appropri
relabel
identifi
lack
adequ
gold
standard
defin
ltbi
must
also
consid
igra
show
greater
specif
tst
sensit
may
compromis
especi
earli
activ
tb
thu
patient
unrecogn
smear
cultur
neg
tb
may
mislabel
symptomat
control
without
ltbi
perform
routin
hiv
test
patient
cohort
possibl
overrepresent
hiv
seroposit
activ
tb
group
may
confound
effect
believ
unlik
view
low
preval
hiv
coinfect
among
tb
patient
peru
found
previou
studi
import
area
futur
studi
establish
applic
approach
context
tbhiv
coinfect
smearneg
tb
present
find
confirm
util
defin
host
proteom
respons
distinguish
clinic
overlap
patient
total
number
masscharg
mz
cluster
obtain
selditof
profil
crude
prefraction
plasma
bracket
number
relev
discriminatori
mz
cluster
select
rfe
algorithm
fraction
ph
fraction
ph
fraction
ph
fraction
ph
fraction
ph
fraction
organ
phase
group
tb
clinic
set
moreov
studi
show
activ
tb
identifi
blood
test
popul
commun
tb
clinic
attend
background
nontb
attribut
symptom
despit
coexist
ltbi
ultim
signific
impact
control
tb
high
preval
set
depend
abil
translat
find
robust
afford
pointofcar
format
incorpor
panel
biomark
deriv
studi
later
flow
devic
similar
platform
logic
next
step
final
util
defin
proteom
pattern
tb
may
extend
beyond
diagnost
provid
new
method
monitor
treatment
respons
diseas
stage
tabl
select
relev
mz
cluster
crude
plasma
xl
